MURA — Mural Oncology Cashflow Statement
0.000.00%
- $35.86m
- -$41.23m
Annual cashflow statement for Mural Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -175 | -190 | -207 | -129 |
| Depreciation | ||||
| Non-Cash Items | 11.5 | 11.9 | 24.1 | 2.5 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 5.79 | 7.75 | -13.5 | -6.05 |
| Change in Accounts Receivable | ||||
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accrued Expenses | ||||
| Change in Payable / Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | -157 | -169 | -194 | -129 |
| Capital Expenditures | -4.38 | -5.51 | -3.45 | -0.092 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | — | — | — | -25.2 |
| Sale of Fixed Assets | ||||
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Cash from Investing Activities | -4.38 | -5.51 | -3.45 | -25.3 |
| Financing Cash Flow Items | 161 | 174 | 469 | — |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Cash from Financing Activities | 161 | 174 | 469 | 0.196 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 0 | 0 | 271 | -154 |